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Abstract
Background:  The anti-tumor efficacy of human immune effector cells, such as cytolytic T
lymphocytes (CTLs), has been difficult to study in lung cancer patients in the clinical setting.
Improved experimental models for the study of lung tumor-immune cell interaction as well as for
evaluating the efficacy of adoptive transfer of immune effector cells are needed.
Methods: To address questions related to the in vivo interaction of human lung tumor cells and
immune effector cells, we obtained an HLA class I + lung tumor cell line from a fresh surgical
specimen, and using the infiltrating immune cells, isolated and characterized tumor antigen-specific,
CD8+ CTLs. We then established a SCID mouse-human tumor xenograft model with the tumor
cell line and used it to study the function of the autologous CTLs provided via adoptive transfer.
Results: The tumor antigen specific CTLs isolated from the tumor were found to have an activated
memory phenotype and able to kill tumor cells in an antigen specific manner in vitro. Additionally,
the tumor antigen-specific CTLs were fully capable of homing to and killing autologous tumors in
vivo, and expressing IFN-γ, each in an antigen-dependent manner. A single injection of these CTLs
was able to provide significant but temporary control of the growth of autologous tumors in vivo
without the need for IL-2. The timing of injection of CTLs played an essential role in the outcome
of tumor growth control. Moreover, immunohistochemical analysis of surviving tumor cells
following CTL treatment indicated that the surviving tumor cells expressed reduced MHC class I
antigens on their surface.
Conclusion:  These studies confirm and extend previous studies and provide additional
information regarding the characteristics of CTLs which can be found within a patient's tumor.
Moreover, the in vivo model described here provides a unique window for observing events that
may also occur in patients undergoing adoptive cellular immunotherapy as effector cells seek and
destroy areas of tumor growth and for testing strategies to improve clinical effectiveness.
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Background
Lung cancer is relatively resistant to currently available
chemotherapy and radiotherapy regimens. However,
observations of lymphocytic infiltrates or generation of
cytotoxic T lymphocytes (CTLs) recognizing lung tumor
antigens in murine and human tumors [1-5] suggest that
an immune reaction could potentially help eliminate
tumor cells. While immune effector cells are present, often
in high numbers, immunological rejection of tumors is
usually not complete, indicating that there may be defects
in the generation or execution of an anti-tumor immune
response [6]. Many factors likely contribute to an incom-
plete immune response including defective processing
and presentation of tumor antigens and loss of MHC class
I antigen expression [7], absence of co-stimulation [8],
absence of tumor reactive T cells [9,10], alteration in T cell
signaling [11-14], presence of a variety of immunosup-
pressive factors [15,16], and inhibition of tumor T cell
infiltration [17,18]. Clearly the dynamics between a grow-
ing tumor and host is very complex and cannot be
explained by a single mechanism. Most of these mecha-
nisms are currently studied in murine tumor models.
There are relatively few reports about the actual events
that occur in situ between human lung tumors and effector
cells of the immune response.
Since the major biological activity against tumors in vitro
and in vivo displayed by tumor infiltrating lymphocytes
(TILs) can be attributed to CD8+ T cells [19], adoptive
immunotherapy using in vitro expanded tumor antigen-
specific CD8+ CTLs, has been considered as a feasible
option for in vivo eradication of tumors [20]. A variety of
lymphoid cells that are able to lyse tumor cells have been
described [19-24]. Furthermore, in humans the in vitro
generation and expansion of autologous CTLs that recog-
nize lung [1-5], melanoma [25-27], renal [28], ovarian
[29], leukemia [30-32], lymphoma [33,34] and breast
[35-38] tumor antigens have now been reported. Since
tumor antigen-specific CTLs are effector cells that are
known to play an important role in inhibiting tumor
growth, it is important to understand the interaction
between tumor-specific CTLs and autologous lung
tumors. Although there were subcutaneous models that
generated to study these interactions [5], it is also impor-
tant to examine the interaction in vivo between these cells
and their target tumor grown orthotopically. The difficul-
ties in studying the interplay between a patient's immune
response and tumors highlights the need to develop an in
vivo model to study the interaction between these cells in
a model which may replicate more closely their environ-
ment in patients.
In this study, primary lung tumor cells and tumor antigen-
specific CTLs isolated from the original surgical specimen
of that same patient's tumor were used as the target and
effector cell, respectively. We demonstrate that the CTLs
were capable of selective homing to and killing autolo-
gous lung tumors grown either subcutaneously or as
experimental metatastases in the lung of SCID mice. We
also observed that there was a defined period of time after
a single injection of CTLs in which the tumor's growth was
inhibited and after this point the tumors regrew. Most
importantly, the MHC class I antigen expression on the
surviving tumor cells was significantly reduced or absent
compared to the original tumor. These data and the use of
this model for development of improved adoptive T-cell
based immunotherapeutic approaches to cancer are dis-
cussed.
Methods
Animals
Six to eight week old male CB17-scid/scid mice used for
this study were obtained from Taconic Labs (German-
town, NY). They were housed in microfilter cages (Lab
Products, Maywood, NJ) at Roswell Park Cancer Institute.
All cages, water, and food (Teklad Mills, Wienfield, NJ)
were supplied after autoclaved. The cages were main-
tained in an air-conditioned and light-controlled (12 h/
day) room and all handling and operations were done in
a laminar flow hood.
Tumor cells
The cell line LT 391-06 was derived from a solid tumor
mass excised from the lung of a patient with large cell lung
carcinoma. The tumor was obtained as a portion of a sur-
gical specimen, minced with scalpels and digested for 4
hours at 37°C in AIM-V (GibcoBRL, Carlsbad, CA) con-
taining Dispase 8 ug/ml (GibcoBRL) Collagenase 100 ug/
ml (GibcoBRL) and Dnase, 10 Ku/ml (Roche). The result-
ant cell slurry was passed through a nylon mesh screen to
break up clumps and layered over two densities of Lym-
phoprep (Axis-Shield, Oslo, Norway). 7 ml of 1.077 den-
sity Lymphoprep was added to a 15 ml conical centrifuge
tube followed by 7 ml of a 75% Lymphoprep, 25% 1 ×
PBS mixture. 10 ml of the cell slurry was layered atop the
Lymphoprep and was separated by density centrifugation.
The layers were collected sequentially with the top layer
containing the majority of tumor cells and the lower layer
containing the majority of TIL. Tumor was resuspended
and cultured in a mixture of 50% F12 nutrient mixture
(GibcoBRL) 50% Basal Medium Eagle (GibcoBRL) 10%
FBS (HyClone, Logan, UT) 100 u/ml Penicillin, 100 ug/
ml streptomycin, 2 mM L-glutamine (GibcoBRL) 5 × 105
β-mercaptoethanol. Tumor cells were incubated at 37°C
and carefully monitored for growth and expansion.
Immunohistochemistry (IHC) was performed by Pheno-
path Laboratories, Seattle, WA in order to confirm that
expanding cell lines indeed arose from a lung carcinoma.
This tumor cell line expresses HLA-A11, B44 and Cw1203.
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removed squamous lung carcinoma lesion and the lung
tumor cell line 81-86T derived from a surgically removed
large cell carcinoma lesion were kindly provided by Dr. Jill
Siegfried of the University of Pittsburgh, Pittsburgh, PA.
The 936T cell line expresses the same tumor antigen that
is expressed by the LT-391 06 cell line, and expresses HLA-
Cw1203 antigen. The cell line 81–86 expresses the tumor
antigen but has a HLA phenotype different from that of
the cell line LT391-06. 81-86-1203 is the lung tumor cell
line 81–86 transfected with HLA-Cw1203 used for posi-
tive control. HLA-Cw1203 stable transfectants of tumor
cells were generated by retroviral transfection resistant to
blasticidin enabling drug selection. A549 is an allogeneic
bronchioalveolar carcinoma cell line purchased from
ATCC (Cat# CCL 185). This tumor cell line is antigen neg-
ative and expresses HLA B44 and Cw1203 antigens. HLA
typing of tumor cells was performed at the Puget Sound
Blood Center in Seattle, WA. Tumor cells were maintained
at 37°C in a 5% CO2 atmosphere in BME/Nutrient mix-
ture F-12 (Life Technologies, Inc., Grand Island, NY), sup-
plemented with 5% heat-inactivated FBS. Cells were
allowed to grow to 80% confluency and were harvested
with 0.25% typsin-1 mM EDTA in HBSS.
Cytotoxic T lymphocytes
Tumor infiltrating lymphocytes (TIL) that the CTLs
derived from were expanded post extraction from the
tumor matrix (described above) and cultured in RPMI
1640 medium (GibcoBRL)containing 10% heat inacti-
vated human serum obtained from an in house donor
pool, 100 u/ml Penicillin, 100 ug/ml streptomycin, 2 mM
L-glutamine (GibcoBRL). The media was supplemented
with 100 u/ml Proleukin IL-2 from (Chiron Therapeutics,
Seattle, WA) and 30 ng/ml Orthoclone OKT3 (Ortho Bio-
tech). Rapidly growing T cells were split upon confluence
and re-fed with fresh media containing a final concentra-
tion of 100 u/ml IL-2 and 30 ng/ml mAb OKT3. Tumor
antigen-specific T cell lines were obtained by stimulating
1.5 × 106 T-cells with 1 × 105 gamma irradiated (20000
rads) autologous tumor cells over a 7-day cycle. The stim-
ulations were performed in 24 well plates, in 2 ml CTL
medium, containing 25 μ/ml IL-2, 10 ng/ml IL-7
(Endogen, Woburn, MA). Media was replaced every 2 – 3
days with IL-2 and IL-7. T cell lines were tested for specif-
icity in a chromium release assay. T cell lines with specific
cytotoxicity were cloned by limiting dilution. Per well, T
cells, 1 × 104 allogeneic irradiated LCL (8000 rads), 7.5 ×
104 allogeneic irradiated PBL (4000 rads) 50 u/ml IL-2
and 30 ng/ml mAb OKT3, 200 ul CTL media per well.
Growth positive wells were tested for specificity in a 5
hour chromium release assay. Responding wells were
expanded in T25 flasks containing 20 ml CTL media, 50
μ/ml IL-2, 30 ng/ml mAb OKT3, 25 × 106 irradiated allo-
geneic PBMC (4000 rads), 5 × 106 allogeneic LCL (8000
rads) and approximately 2 × 105 of the specific clone. V-
beta analysis performed upon isolated clones by flow
cytometry confirmed the homogeneity of the clone.
Expanded cells were viably frozen in 90% Fetal Calf
Serum (HyClone, Logan, UT) and 10% DMSO (Sigma
Chemical co, St Louis, MO). Cells were thawed and rested
24 hours in CTL media containing 25 μ/ml IL-2 prior to
each use. Anti-LT391-06 CTL is tumor antigen specific
CD8+ T cell clone derived from TILs of lung tumor patient
number LT391-06. This clone recognizes a unique shared
antigen restricted by HLA-Cw1203 antigen. Studies to
identify more precisely this antigen are currently in
progress. A CD8+ T cell clone which recognizes an influ-
enza nucleoprotein specific antigen restricted by HLA-B27
antigen was used as a control. Cells were cultured at 37°C
in a 5% CO2 atmosphere in RPMI 1640 medium (Life
Technologies, Inc.) supplemented with 10% heat-inacti-
vated FBS.
Antibodies
Antibodies for phenotyping the cell surface of CTLs
included mouse anti human CD2, CD3, CD4, CD8,
CD11a (LFA-1), CD25 (IL-2Rα), CD27, CD28, CD29 (β1-
integrin), CD44, CD45RO, CD45RA, CD49a (α1
integrin), CD49b (α2 integrin), CD49d (α4 integrin),
CD49e (α5 integrin), CD49f (α6 integrin), β7-integrin,
CD54 (ICAM), CD56 (NCAM), CD62L (L-selectin),
CD69, CD95 (Fas), CD95L (FasL), CD122 (IL-2Rβ),
CD132 (IL-2Rγc), CD134 (OX40), CD152 (CTLA-4),
CD154 (CD40L), CD161 (NK1.1), IL-6R, IL-9R, IL-10R,
CCR5, CCR7, CXCR3 and MHC Class 1 antigens. All these
antibodies were purchased from BD-Pharmingen (San
Diego, CA). The mAb HC10 which recognizes a determi-
nant expressed on all β2-microglobulin-free HLA-B and
HLA-C heavy chains, as well as on β2-microglobulin-free
HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-
A32, and HLA-A33 heavy chains was developed and char-
acterized as described [39,40].
Flow cytometry
Single color staining was performed by incubating 5 × 105
viable cells with an optimal amount of fluorescence-cou-
pled antibodies. After several washes, approximately
10,000 cells per sample were analyzed on a FACScan
(Beckton Dickinson, San Jose, CA).
Cytokine measurement
Supernatant cytokine release was determined by sandwich
ELISA. Serial dilutions of samples were analyzed for IFN-
γ and TNF-α. Antibodies were purchased from BD-
Pharmingen.
Chromium release assay
Tumor cells were labeled with 3.7 MBq (100 μci) 51Cr for
1 hr at 37°C. Tumor cells were washed and re-suspended
in RPMI 1640 medium supplemented with 10% FBS.Journal of Translational Medicine 2007, 5:29 http://www.translational-medicine.com/content/5/1/29
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After counting, CTLs were placed in 96 well plates. Subse-
quently 51Cr labeled tumors cells were added to appropri-
ate wells. Following a 5 hr incubation at 37°C in a 5%
CO2 atmosphere, plates were centrifuged at 400 rpm for 5
min. The supernatant of each well was collected individu-
ally and the 51Cr release was assessed in a gamma counter.
The percentage of specific 51Cr release was calculated
using the standard formula: %51Cr release = [(51Cr release
of samples-spontaneous 51Cr release)/(maximum 51Cr
release-spontaneous 51Cr release)] ×100. All samples were
run in quadruplicate in two different sets of experiments.
Tumor growth
One hundred μl of a lung tumor cell suspension (at a con-
centration of 5 × 106/ml) were injected subcutaneously or
intravenously into SCID mice. Subcutaneously grown
tumors were measured with a venier caliper to determine
the shortest diameter (A) and the longest diameter (B).
The volume was then calculated by using the formula V =
(A2B)/2. For intravenously grown tumor, lung were
excised and weighed.
Depletion of murine NK cells
To deplete NK cell activity, 24 h before injection of tumor
cells, we injected every 4 weeks i.p 100 μl of TMβ-1 anti-
body obtained as ascites fluid from a hybridoma kindly
provided to Dr. Richard Bankert (State University of New
York at Buffalo, Buffalo, NY) by Dr. T. Tanaka (Tokyo Met-
ropolitan Institute of Medical Science, Tokyo, Japan). This
antibody blocks murine IL-2β receptor and exhibits no
crossreactivity with human IL-2β receptor [41].
IL-2 treatment
Subcutaneous tumor bearing SCID mice, previously
treated with TM-β1 antibody, received daily subcutaneous
injections of 20,000 IU of Proleukin IL-2 (Chiron Thera-
peutics, Seattle, WA) starting the day of adoptive transfer
of CTLs.
Histopathology
After animals were sacrificed, tumor and lung or other
organs were excised for histological analysis. Excised tis-
sues were fixed for 24 h in 10% buffered formalin. The tis-
sues were then dehydrated for 18 h by an automatic tissue
processor and embedded in paraffin blocks. Five-microm-
eter paraffin tissue sections were cut and the tissue sec-
tions were stained with hematoxylin and eosin.
Immunohistochemical analysis
Immunohistochemical analysis was performed according
to the staining procedure for paraffin sections provided by
Vector Laboratories (Burlingame, CA). Briefly, paraffin
sections (5 μm) were deparaffinized and rehydrated
through xylene and alcohol series. The tissue sections
were then incubated with 0.3% H2O2 in methanol for 30
min to quench endogenous peroxidase activity and then
incubated with diluted normal goat serum for 20 min to
block nonspecific bindings. The sections were then incu-
bated at room temperature for an hour with anti-HLA
class I heavy chain mAb HC-10 or CD8 (Novocastra Lab-
oratories Ltd., Newcastle, UK). Biotinylated goat anti-
mouse IgG antibodies (at a1:500 dilution) were then
applied to tissue sections for 30 min at room temperature.
Vectorastain ABC kit (Vector Laboratories, Burlingame,
CA) was used for signal enhancement and peroxidase sub-
strate DAB was used for color development.
RT-PCR
Total RNA was extracted from lung and liver of SCID mice
baring tumor and/or CTL and RT-PCR was done as per
manufacturer's instructions (Superscript Preamplification
System; Life Technologies, Inc). Primers for human CD8
were: 5'-TTTAGCCTCCCCCTTTGTAAAACGGGCG-3' and
5'-TTTCGGCGAGATACGTCTAACCCTGTGC-3'. Primers
for human IFN-γ were: 5'-CTCCTTTTTCGCTTCCCTGTTT-
TAGCTGCTGG-3' and 5'-GCATCGTTTTGGGTTCTCTT-
GGCTGTTACTGC-3'. Primers for β-actin were: 5'-
ATCTGGCACACCTTCTACAATGAGCTGCG-3' and 5'-
CGTCATACTCCTGCTTGCTGATCCACATCTGC-3'.
Amplification was done for 35 cycles with denaturing at
94°C for 30 s, annealing at 60°C for 1.5 min, and exten-
sion at 72°C for 1.5 min.
Statistical analysis
Statistical analysis was conducted using two methods. For
lung weights we used non-parametrical unpaired Student
t-test analysis. For analysis of sc models we took the refer-
ence as the day for tumors to reach 500 mm3 in volume
using the long rank test provided in the Graphpad Prism
Software Package version 4.01 (Graphpad, San Diego,
CA). P values < 0.05 referred as statistically significant.
Results
Patient derived CTLs express an activated memory 
phenotype and kill autologous lung tumor cells in vitro
When patients undergo CTL adoptive therapy, CTLs are
usually obtained from the tumor and expanded in vitro to
obtain a sufficient number of cells. To investigate param-
eters associated with adoptive immunotherapy of a
patient's CTLs, we used a SCID mouse model bearing the
autologous lung tumor. Briefly, we used the TILs derived
from a patient's lung tumor to obtain a population of
CTLs for expansion. We first characterized the cell surface
markers of the CTLs that we expanded in vitro. Our analy-
sis revealed that these expanded CTLs have an activated
memory phenotype and maintain the phenotype of the
CTLs originally isolated TILs: CD3+ CD8+ CD25+ CD27-
CD44+ CD69+CD62L-CD45RA- CD45RO+ CCR5+ CCR7+.Journal of Translational Medicine 2007, 5:29 http://www.translational-medicine.com/content/5/1/29
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In order to determine whether these HLA-Cw1203
restricted CTLs were capable of recognizing and respond-
ing to tumor cells, they were co-cultured with tumor cells
that either expressed or did not express the appropriate
restriction element. In the presence of autologous tumor
cells these CTLs produced IFN-γ and TNF-α in tissue cul-
ture supernatant (Fig 1A) and were able to specifically lyse
tumor cells in vitro as demonstrated in a chromium release
assay (Fig 1B). CTLs were neither able to produce IFN-γ
and TNF-α nor lyse tumor cells that lacked the appropriate
restriction element (Fig 1A, B).
Tumor infiltration by tumor antigen-specific CTLs
We next investigated the ability of these CTLs to localize
at the site of orthotopically grown autologous lung tumor
cells in SCID mice. In preliminary experiments, we found
that when these tumor cells were injected intravenously
they seeded to the lungs and formed established tumor
foci by day 5 (data not shown). Therefore, we chose to
adoptively transfer CTLs via tail vein injection at day 5.
Lungs and other organs were recovered from mice at day
10 and examined for the presence of CD8 + CTLs by
immunohistochemistry and RT-PCR analysis. We found
that CTLs homed and persisted only to the tumor bed in
Tumor antigen-specific CTLs release cytokines and exert cytotoxic activity when incubated in vitro with autologous tumor cells Figure 1
Tumor antigen-specific CTLs release cytokines and exert cytotoxic activity when incubated in vitro with autologous tumor cells. 
A. CTLs (1 × 104) were incubated with an equal number of 81–86 (allogeneic tumor, a negative control), 81-86-1203 tumor 
cells (allogeneic tumor transfected with HLA-Cw1203, a positive control), or LT-391-06 tumor cells (autologous tumor). CTLs 
and tumor cells were also incubated alone as controls. Cells were incubated overnight at 37°C. Supernatants were analyzed by 
sandwich ELISA for the presence of IFN-γ and TNF-α. B. The cytotoxic activity of CTLs was analyzed by a 51chromium release 
assay. Serial dilutions of CTLs (starting from 1 × 104) were incubated with either (1 × 103) LT-391-06 (●) or Daudi (▲, nega-
tive control) or K562 (■, negative control).
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the lungs (Fig 2A and 2E) but were not found in the liver
(Fig 2E), as determined not only by microscopic analysis
of multiple sections (data not shown) but also by the
complete lack of human β-actin expression in liver (Fig
2G). Immunohistochemical analysis demonstrated that
while tumor antigen-specific CD8+ CTLs injected on day 5
localized and persisted within the lung tumor at day 10
(Fig. 2A), flu-specific CTLs were not found in the lung
tumor examined on the same day (Fig 2C). As expected,
the lungs of the mice that were injected with only tumor
cells but not CTLs as a control did not stain for the CD8
marker (Fig 2B and 2E). CD8+ CTLs did not accumulate
in the lungs of non-tumor bearing mice (Fig 2D). These
results indicate a requirement for the presence of an
appropriate antigen at the site of the lung for sustaining
the presence of the reactive CTLs in this site. We observed
human IFN-γ expression in lungs bearing both autologous
tumors and tumor antigen-specific CTLs, but not in lungs
bearing tumor only (Fig 2F). These data show that a lung
tumor cell line derived from a patient's lung tumor can be
tumorigenic and colonize the lung of SCID mice. In addi-
tion, autologous tumor antigen-specific CTLs can home to
and persist in these established tumors. Moreover, specific
production of cytokines from tumor antigen-specific CTLs
is consistent with the conclusion that the autologous
tumor cells continued to express the tested tumor antigen
when grown as xenografts. The ability of CTLs to express
IFN-γ only in the presence of tumor suggests that the CTLs
remain functional following adoptive transfer to SCID
mice.
Anti-tumor effect of CTLs on established lung tumors in 
vivo
To determine whether tumor antigen-specific CTLs could
inhibit tumor growth in vivo we injected mice with autol-
ogous tumor cells on day 0 and CTLs on day 5 intrave-
nously. On day 35 lungs were removed and based on lung
weight measurements (Fig. 3A) and histological analysis
(Fig. 3B), we found that a single dose of CTLs was effective
in suppressing the growth of lung tumors. To confirm that
this CTL-mediated tumor suppression is tumor antigen-
specific in vivo, we used two allogeneic cell lines as con-
trols. 936T lung tumor cells shared the same antigen and
expressed HLA-Cw1203 whereas A549 tumor cells did
not. These tumor cells were each co-injected with LT391-
06-specific CTLs. LT391-06-specific CTLs inhibited in vivo
the growth of HLA-matched allogeneic cells expressing
antigen 936T (Fig 4B), but had no detectable effect on the
growth of HLA-matched allogeneic tumor cells lacking
antigen A549 (Fig 4A).
Effect of timing and frequency of CTL injections on 
established lung tumor growth
Next, we investigated whether additional injections or dif-
ferent schedules of CTL injection could improve the effi-
cacy of tumor suppression. Figure 5 compares the lung
weights of control animals (Group 1) with animals
injected with tumor only (Group 2). In figure 5A tumor
bearing animals were subjected to CTL injection either on
day 5 (Group III) or on day 15 (Group IV) or both on days
5 and 15 (Group V). Based on these lung weight measure-
ments on day 30, we found that administration of CTLs
on day 5 resulted in a significant inhibition of tumor
growth in comparison to administration of CTLs on day
15; in the latter case CTLs had no significant effect on
tumor growth. In addition, injection of CTLs on both day
5 and 15 did not significantly enhance the anti-tumor
effect in comparison with CTLs injected only on day 5.
These results indicate that the timing of CTL injection is
critical for suppression of tumor growth (Fig 5A). Since,
two injections of CTLs spaced 10 days apart were not more
effective than one injection on day 5, we specifically inves-
tigated the effect of frequency of CTL injection on antitu-
mor activity. One dose of CTLs on Day 3 resulted in
significant tumor growth inhibition which was not
enhanced by additional doses on successive days (Fig 5B).
We also examined the effect of daily injection of 20,000
IU of IL-2 on antitumor activity of CTLs and found that
injection of IL-2 for three weeks did not enhance their
antitumor activity (data not shown).
Decrease in surface HLA class I expression in lung tumor 
treated with tumor antigen-specific CTLs
Tumor growth in the SCID mouse model utilized is sup-
pressed by tumor antigen-specific CTL in a dose depend-
ent fashion for approximately 40 days (Fig 6A). After this
time interval, the growth rate of tumors undergoes a rapid
acceleration. Since defects in HLA class I antigen expres-
sion have been identified as an escape mechanism under-
lying tumor progression in spite of a tumor antigen-
specific CTL response, we asked whether tumors which
continued to progressed after treatment with CTLs under-
went alteration of HLA class I expression. As shown in Fig
6C, HLA class I expression is significantly reduced in
tumor cells grown in the presence of tumor antigen-spe-
cific CTLs. The effect is specific since no significant change
in HLA class I expression was detected in the presence of
influenza specific CTL (Fig 6A). These results were notable
because the tumor cells that we prepared for these experi-
ments were originally positive for HLA class I expression
in vitro and remained positive by IHC in untreated mice
(data not shown).
Discussion
Despite theoretical appeal and actual data regarding the
efficacy of T cell-mediated immunotherapy, only a small
subset of human cancer patients who present with tumors
actually experience clinically relevant benefits. The results
of our studies presented here indicate that tumor antigen-
specific, HLA-Cw1203 restricted CTLs, generated from theJournal of Translational Medicine 2007, 5:29 http://www.translational-medicine.com/content/5/1/29
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cells that infiltrate a patient's lung tumor, are able to lyse
autologous lung tumor cells in vitro and in a SCID mouse
model. Consistent with these findings, in humans the in
vitro generation and expansion of autologous CTLs that
recognize lung [1-5], melanoma [25-27], renal [28], ovar-
ian [29], leukemia [30-32], lymphoma [33,34] and breast
[35-38] tumor antigens have been reported. Furthermore,
studies using patients' melanoma tumors [42,43] or
revealed that melanoma antigen-specific CTLs killed allo-
geneic melanoma cells which shared the HLA class I
restricting element, to a similar extent as autologous
melanoma cells. Other studies showed that CTLs can be
effective cytotoxic effector cells for adoptive immuno-
therapy [19-24] as well.
Phenotypic analysis has often been utilized to characterize
the differentiation, proliferation, activation status and
immune response of a particular immune cell. Since there
was no prior information about the phenotypic character-
istics of lung tumor derived, tumor antigen-specific CD8+
CTLs, we needed to first characterize the cell surface mark-
ers of the patient derived and in vitro-expanded CTLs. A
previous study, which investigated the functions of CD8+
T cell CD27+CD45RA+  subsets, suggested that
Tumor antigen-specific CTL and expression of cytokines are detected in the lungs of SCID mice bearing autologous lung tumor Figure 2
Tumor antigen-specific CTL and expression of cytokines are detected in the lungs of SCID mice bearing autologous lung 
tumor. Mice were injected with 5 × 105 tumor cells intravenously. On day 5, after tumor foci were established in the lungs, 5 × 
106 CTLs were injected intravenously. On day 10, mice were sacrificed and lung and liver were excised for immunohistochem-
ical and PCR analysis. A, B, C and D. IHC analysis of lungs for the presence of CD8 positive CTLs. Lungs from mice injected 
with A. tumor cells + tumor antigen-specific CTLs B. tumor cells only, C. tumor cells + influenza nucleoprotein antigen-spe-
cific CTL or D. tumor antigen-specific CTL alone. Original magnification: ×200, brown staining shows CD8 positive T cells. E, 
F and G. RT-PCR analysis. Primers used are specific for human E. CD8, F. IFN-γ and G. β-actin. Lane 1, 100 bp DNA ladder; 
lane 2, cDNA from lung of SCID mice bearing human tumor only; lane 3, cDNA from liver of SCID mice bearing with tumor 
only; lane 4, cDNA from lung of SCID mice bearing human tumor and CTLs; lane 5, cDNA from liver of SCID mice bearing 
tumor and CTLs.
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CD27+CD45RA+CD8+  T cells are naïve T cells, while
CD27+CD45RA-CD8+, CD27-CD45RA-CD8+, and CD27-
CD45RA+CD8+ T cells are memory, memory/effector and
effector cells, respectively [44]. Classification is made on
virus epitope specific CD8+ T cells based upon CCR5 and
CCR7 expression indicates that CCR5 expression is
restricted to memory and effector cells, whereas CCR7 is
expressed only in naïve and memory cells [45]. The infor-
mation we gathered after phenotypic analysis of CTLs
revealed that these CD8+  T cells were CD25+CD27-
CD45RA-CD45RO+CD44+CD69+  CCR5+CCR7+, and
based on the previous studies [45] we can conclude that
these cells have an activated memory phenotype, again
suggesting that within the patient, positive immune stim-
ulation took place at some point in the course of the dis-
ease. Yet, for many patients, and for reasons which are not
yet clear, these cells fail to control tumor growth.
It has been difficult to study the antitumor efficacy of
human immune effector cells, such as cytolytic T lym-
phocytes (CTLs) in the clinical setting of lung cancer and
there has been little information derived from animal
models in this regard and the models that have been
developed utilizes subcutaneously grown tumors [5,46].
SCID mice that lack functional T and B cells have been
shown to be useful hosts to grow human tumors, both
from established cell lines and from tumors obtained
directly from patients [46-53]. Thus, they may provide an
environment for studying the interactions between
human tumor cells and autologous tumor antigen-spe-
Tumor specific CTLs suppress the growth of autologous lung tumors in SCID mice Figure 3
Tumor specific CTLs suppress the growth of autologous lung tumors in SCID mice. SCID mice were injected with 5 × 105 
tumor cells intravenously. At day 5, after tumor foci were established in the lungs, mice were received either 5 × 106 tumor 
specific or anti-flu CTLs (i.v. injection). At day 20 and 35, 6 mice from each group (I. control; II. tumor only; III. tumor plus flu-
specific CTL or IV. tumor plus tumor-specific CTL were sacrificed and lung and liver were excised for further studies. A. Lung 
weights; B. Histology of normal lung; C. Histology of lung from tumor bearing mice treated with anti-flu specific CTLs and D. 
Histology of lung from tumor bearing mice treated with tumor specific anti-LT391-06 CTLs. Differences in lung weight 
between groups was evaluated by the student t-test: II versus III, P < 0.95; II vs. IV, P < 0.001; III vs. IV, P < 0.004.
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cific CTL. In evaluating the efficacy of these tumor anti-
gen-specific CTLs in vivo by adoptively transferring them
to SCID mice, we found that these CTLs possessed remark-
able efficiency at homing to and remaining in the lung
bearing autologous tumors (orthotopically grown
tumors). Notably, they did not persist in non-tumor bear-
ing lungs or liver. Most importantly, a single injection of
these cells, with no further supportive treatments with IL-
2 resulted in significant tumor growth suppression in
both subcutaneously grown tumor and lung tumor metas-
tasis. Future studies should evaluate other cytokines such
as IL-15 in terms of improving CTL effectiveness.
One possibility for improvement of the response may be
related to timing of immune treatment since based on our
results, the scheduling of CTL injection was found to be
very critical in delaying tumor growth. If tumor antigen-
specific CTLs are generated early enough they may be
more effective in controlling tumor growth. Another obvi-
ous reason for incomplete cure could be the limited sur-
vival of CTLs in vivo. Improving the survival of CTLs in this
setting remains for further investigation. The number of
CTLs is another issue that needs to be considered; in all
our experiments we administered a maximum dose of 5 ×
106 CTLs. In future experiments, it is essential to know
whether the tumor growth will be further inhibited by
using a higher dose of CTLs. Notably however, adminis-
tration of CTLs at consecutive time points did not signifi-
cantly enhance the antitumor effect compared to a single
injection of CTLs at an early time point. This may be due
to the fact that the first injection resulted in the majority
of the effect and that possible tumor cell phenotype
changes occurring after the first CTL treatment provided
tumor cells with escape mechanisms from recognition
and destruction by subsequently administered CTLs.
Any effective CD8+ T cell based-immunotherapy depends
on the continued HLA class I antigen expression by tumor
cells [7,54]. Although loss of HLA class I antigen expres-
sion is previously described in patient tumors [7], this
study is the first study to show patients' HLA Class I posi-
tive lung tumor cells following tumor antigen-specific
CTL treatment showed marked decreased HLA class I
expression using this mouse model. Whether this change
represents a general phenomenon is not known at
present. Nevertheless our results suggest that the applica-
The anti-tumor effect of anti-LT391-06 CTLs against two HLA matched allogeneic tumor cells is antigen specific Figure 4
The anti-tumor effect of anti-LT391-06 CTLs against two HLA matched allogeneic tumor cells is antigen specific. SCID mice in 
control groups (●) received a s.c. injection of 5 × 105 tumor cells alone and mice in the treated groups (❍) received a co-injec-
tion of 1 × 106 anti-LT391-06 CTLs s.c. A. Mice bearing A549 tumors, an allogeneic bronchioalveolar carcinoma cell line which 
does not express the LT391-06 Ag recognized by the tumor specific CTLs; B. Mice bearing 936T, an allogeneic tumor cell line 
derived from a squamous lung carcinoma which does express this antigen. (n = 5 mice/group)
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tion of T cell selective pressure to a tumor cell population
favours the outgrowth of tumor cells with defects in HLA
class I antigen expression. At this point, we cannot distin-
guish between selection and ongoing mutation as the
major mechanism for this effect. However, Kedl et al [55]
have shown down-modulating peptide MHC class I com-
plexes on APCs by high affinity T cells in vivo. Since we
were still able to detect cytoplasmic but not membrane
staining with anti-HLA class I mAb in some of the tumor
cells, it is possible that a similar phenomena might be
occurring after tumor antigen-specific CTL interaction
with autologous tumor cells. In this study, we have not
been able to look at changes in tumor antigen expression
because we are still in the process of characterizing tumor
antigen-specific antibodies. The mechanism(s) underly-
ing decreased HLA class I expression on lung tumor cells
is not known. The phenotype of the lung tumor cells we
have analyzed in conjunction with the described high fre-
quency of antigen processing machinery abnormalities in
tumor cells suggest that defects in this machinery may
underlie the HLA class I antigen downregulation we have
detected in tumor cells following treatment with tumor
antigen-specific CTL. If our hypothesis is correct, the
defects in the antigen processing machinery which result
in defective loading of HLA class I antigens with peptides
and in their instability on the cell membrane may be cor-
rected by IFN-γ. Another explanation of decreased MHC
class I expression can be the selection of MHC class I neg-
ative variants of the tumor. The concept of selection for
tumor cells or shaping the tumor immunogenicity has
been previously described [56]. Using this model, ways
could be tested to evaluate the ability of various adjuvants
for their ability to increase expression of MHC class I. For
example, tumor cells have been shown to upregulate their
MHC class I expression after IFN-γ treatment [56-58]. An
alternative strategy could rely on the enhancement of the
lytic activity of natural killer (NK) cells, since HLA class I
antigen downregulation and loss enhance susceptibility
of target cells to NK cell-mediated lysis.
Conclusion
These studies confirm and extend previous studies and
demonstrate the ability of a patient's lung-tumor derived
CTLs to specifically home to a orthotopically grown
xenograft composed of the autologous tumor cells, sup-
press tumor growth and express IFN-γ in vivo without the
administration of exogenous human cytokines. Moreover,
these study shows killing of lung tumors mediated by
CTLs can shape the phenotype of the tumors and result in
tumor growth with decreased HLA Class I expression.
Although caution should be exercised in interpreting
these data since they derive from only one patient's lung
tumor, the approach developed here could be used for
additional patients and thus contribute to our under-
standing of the potential of adoptively transferred CTLs in
the immunological control of tumor growth. Lastly, these
studies provide hope that additional work maximizing
the long-term effectiveness of this type of treatment will
provide important clues toward development of
improved adoptive immunotherapy strategies for humans
with lung cancer.
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The anti-tumor effect of CTLs on autologous tumor  xenografts is dependent on the time of administration, but  not the number of doses Figure 5
The anti-tumor effect of CTLs on autologous tumor 
xenografts is dependent on the time of administration, but 
not the number of doses. A. Mice (5/group) received 5 × 105 
tumor cells (i.v.). Once tumors were established in the lung, 
three of these groups (5 mice/group) were injected with 
CTLs (5 × 106): Group III on day 5, Group IV on day 15 and 
Group V on both days 5 and 15. (The control group I did not 
receive tumor, Group II received tumor but not CTLs). At 
day 30, mice were sacrificed and lungs were excised and 
weighed. Differences in lung weight between treatment 
groups were evaluated by the Student t-test: I vs. II, P < 
0.001; I vs. III, P < 0.1; I vs. IV, P < 0.001; II vs. IV, P < 0.35; III 
vs. IV, P < 0.001. B. Mice (groups II-IV, 5 mice/group) were 
injected with 5 × 105 tumor cells (i.v.). After lung tumors 
were established, 4 groups (III-VI) received CTLs (5 × 106) as 
follows: Group III – one dose of CTL on day 3; Group IV – 
days 3 and 4; Group V-days 3, 4 and 5; Group VI-days 3, 4, 5 
and 6. Normal lung weight was derived from Group I, which 
did not receive tumor cells; Group II received PBS and no 
CTL. On day 30, mice were sacrificed and lungs were excised 
and weighed. The growth of lung tumors in mice treated with 
tumor specific CTLs was significantly inhibited by one dose 
on day 3; there was no advantage to the administration of 
additional CTL doses.
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